Michael Huntgeburth1,2, Christopher Hohmann1, Harald Kaemmerer2, Christof Kolb3, Peter Ewert2, Sebastian Freilinger2, Nicole Nagdyman2, Rhoia Neidenbach2, Lars Pieper4, Felix Pieringer2, Carsten Lennerz3. 1. Center for Adults with Congenital Heart Disease, Clinic III for Internal Medicine, Department of Cardiology, Heart Center, Medical Faculty, University Hospital of Cologne, Cologne, Germany. 2. Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany. 3. Department of Electrophysiology, German Heart Center Munich, Technical University of Munich, Munich, Germany. 4. Chair of Behavioural Epidemiology, Institute of Clinical Psychology and Psychotherapy, Technical University of Dresden, Dresden, Germany.
Abstract
BACKGROUND: Patients with congenital heart defects (CHD) are prone to residua, sequels and complications from the underlying anomaly, where cardiac arrhythmias are one of the major causes for hospitalization, morbidity and mortality. The importance of the subcutaneous implantable loop recorder (ILR) for the detection and documentation of significant arrhythmias has increased over the last years. To date, however, there is little data on ILR use in the CHD population. METHODS: In this single center, retrospective observational study, all CHD-patients with an ILR were identified who were under care of the German Heart Center Munich between February 2015 and January 2019. The primary endpoint of the study was the detection or exclusion of significant arrhythmias during follow-up in CHD-patients who had received an ILR. The secondary endpoint was to determine whether ILR findings influenced patient management, defined as initiation or adjustment of medication, cardioversion, electrophysiologic study, catheter ablation, or implantation of cardiac implantable electronic devices (CIEDs) such as pacemakers (PM) or implantable cardioverter-defibrillators. RESULTS: An ILR was implanted in 33 CHD-patients (mean age, 43±20 years; 42.4% female) with CHD. During a mean observation period of 697±433 days, clinically relevant arrhythmias, correlating with the patients' complaints and symptoms, were detected in 19 patients (59.4%), encompassing supraventricular tachycardia (n=10), supraventricular or ventricular ectopic beats (n=10), non-sustained ventricular tachycardia (n=2), ventricular tachycardia (n=2), and bradycardia (n=2). In 9 patients (28.1%) the detected arrhythmia was considered an event requiring treatment. Treatment modalities included catheter ablation (n=5), modification of antiarrhythmic drug regime (n=2), adaptation of anticoagulation therapy (n=2), or implantation of a subcutaneous ICD (n=1). Regarding the occurrence of cardiac arrhythmias or a related need for therapeutic intervention, no significant differences were identified with respect to WHO functional class, the presence of pulmonary arterial hypertension or reduced resting peripheral oxygen saturation. CONCLUSIONS: In symptomatic CHD-patients at risk for life-threatening cardiac events, ILR has a considerable complementary diagnostic value for the detection and differentiation of benign and malignant arrhythmias. Considering the overall low risk of complications, ILR implantation should be considered in patients with CHD of any complexity who need medium or long-term arrhythmia monitoring, especially if short-term Holter monitoring cannot provide sufficient diagnostic certainty. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: Patients with congenital heart defects (CHD) are prone to residua, sequels and complications from the underlying anomaly, where cardiac arrhythmias are one of the major causes for hospitalization, morbidity and mortality. The importance of the subcutaneous implantable loop recorder (ILR) for the detection and documentation of significant arrhythmias has increased over the last years. To date, however, there is little data on ILR use in the CHD population. METHODS: In this single center, retrospective observational study, all CHD-patients with an ILR were identified who were under care of the German Heart Center Munich between February 2015 and January 2019. The primary endpoint of the study was the detection or exclusion of significant arrhythmias during follow-up in CHD-patients who had received an ILR. The secondary endpoint was to determine whether ILR findings influenced patient management, defined as initiation or adjustment of medication, cardioversion, electrophysiologic study, catheter ablation, or implantation of cardiac implantable electronic devices (CIEDs) such as pacemakers (PM) or implantable cardioverter-defibrillators. RESULTS: An ILR was implanted in 33 CHD-patients (mean age, 43±20 years; 42.4% female) with CHD. During a mean observation period of 697±433 days, clinically relevant arrhythmias, correlating with the patients' complaints and symptoms, were detected in 19 patients (59.4%), encompassing supraventricular tachycardia (n=10), supraventricular or ventricular ectopic beats (n=10), non-sustained ventricular tachycardia (n=2), ventricular tachycardia (n=2), and bradycardia (n=2). In 9 patients (28.1%) the detected arrhythmia was considered an event requiring treatment. Treatment modalities included catheter ablation (n=5), modification of antiarrhythmic drug regime (n=2), adaptation of anticoagulation therapy (n=2), or implantation of a subcutaneous ICD (n=1). Regarding the occurrence of cardiac arrhythmias or a related need for therapeutic intervention, no significant differences were identified with respect to WHO functional class, the presence of pulmonary arterial hypertension or reduced resting peripheral oxygen saturation. CONCLUSIONS: In symptomatic CHD-patients at risk for life-threatening cardiac events, ILR has a considerable complementary diagnostic value for the detection and differentiation of benign and malignant arrhythmias. Considering the overall low risk of complications, ILR implantation should be considered in patients with CHD of any complexity who need medium or long-term arrhythmia monitoring, especially if short-term Holter monitoring cannot provide sufficient diagnostic certainty. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: Sing-Chien Yap; Jolien W Roos-Hesselink; Elke S Hoendermis; Werner Budts; Hubert W Vliegen; Barbara J M Mulder; Arie P J van Dijk; Martin J Schalij; Willem Drenthen Journal: Eur Heart J Date: 2006-10-09 Impact factor: 29.983
Authors: Karen K Stout; Curt J Daniels; Jamil A Aboulhosn; Biykem Bozkurt; Craig S Broberg; Jack M Colman; Stephen R Crumb; Joseph A Dearani; Stephanie Fuller; Michelle Gurvitz; Paul Khairy; Michael J Landzberg; Arwa Saidi; Anne Marie Valente; George F Van Hare Journal: Circulation Date: 2019-04-02 Impact factor: 29.690
Authors: Jim T Vehmeijer; Tom F Brouwer; Jacqueline Limpens; Reinoud E Knops; Berto J Bouma; Barbara J M Mulder; Joris R de Groot Journal: Eur Heart J Date: 2016-02-11 Impact factor: 29.983
Authors: Rafi Sakhi; Robert M Kauling; Dominic A Theuns; Tamas Szili-Torok; Rohit E Bhagwandien; Annemien E van den Bosch; Judith A A E Cuypers; Jolien W Roos-Hesselink; Sing-Chien Yap Journal: Int J Cardiol Date: 2020-02-04 Impact factor: 4.164
Authors: Vassilios J Bezzerides; Amy Walsh; Maria Martuscello; Carolina A Escudero; Kimberlee Gauvreau; Geralyn Lam; Dominic J Abrams; John K Triedman; Mark E Alexander; Laura Bevilacqua; Douglas Y Mah Journal: JACC Clin Electrophysiol Date: 2019-02
Authors: Petra Opić; Elisabeth M W J Utens; Philip Moons; Dominic A M J Theuns; Arie P J van Dijk; Elke S Hoendermis; Hubert W Vliegen; Natasja M S de Groot; Maarten Witsenburg; Martin Schalij; Jolien W Roos-Hesselink Journal: Clin Res Cardiol Date: 2012-07 Impact factor: 5.460